Related Experiment Videos
Immunosuppression following cardiac transplantation
S L Woodley1, D G Renlund, J B O'Connell
1Division of Cardiology, University of Utah School of Medicine, Salt Lake City.
Cardiology Clinics
|February 1, 1990
Summary
Immunosuppression after heart transplant involves early rejection prevention, chronic maintenance, and treating rejection episodes. Current strategies include triple therapy, with potential for corticosteroid-free maintenance and personalized future treatments.
Area of Science:
- Immunology
- Cardiology
- Transplantation Medicine
Background:
- Cardiac transplantation requires immunosuppression to prevent allograft rejection.
- Immunosuppressive strategies are categorized into early prophylaxis, chronic maintenance, and treatment of rejection episodes.
Purpose of the Study:
- To outline the current approaches to immunosuppression in cardiac transplantation.
- To discuss the components and evolution of immunosuppressive protocols.
Main Methods:
- Review of standard immunosuppressive regimens used post-cardiac transplantation.
- Description of agents including cyclosporine, azathioprine, corticosteroids, and anti-T cell therapies (e.g., OKT3).
Main Results:
- Early prophylaxis typically involves triple therapy (cyclosporine, azathioprine, corticosteroids) +/- anti-T cell agents.
- Chronic maintenance commonly utilizes triple therapy, with corticosteroid-free options emerging.
- Acute rejection treatment involves dose optimization, corticosteroid augmentation, and potential anti-T cell therapy.
Conclusions:
- Current immunosuppression protocols are well-defined for early, maintenance, and treatment phases.
- Individualization of immunosuppressive therapy is a future direction in cardiac transplantation.